Peer-reviewed published
|
 |
 |
Monoamine depletion by reuptake inhibitors Abstract: Disagreement exists regarding the etiology of cessation of the observed clinical results with administration of reuptake inhibitors. Traditionally, when drug effects wane, it is known as tachyphylaxis. With reuptake inhibitors, the placebo effect is significantly greater than the drug effect in the treatment of depression and attention deficit hyperactivity disorder, leading some to assert that waning of drug effects is placebo relapse, not tachyphylaxis. |
|
APRESS: apical regulatory super system, serotonin,
and dopamine interaction Abstract: The most significant aspect of this paper is the documentation of newly recognized relationships between serotonin and dopamine. When transport of serotonin and dopamine are both in the competitive inhibition state, manipulation of the concentrations of one will lead to predictable changes in concentrations of the other. From a functional standpoint, processes regulated and controlled by changes to only serotonin can now be controlled by changes to dopamine, and vice versa, in a predictable manner. |
|
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model” Abstract: Spot baseline urinary monoamine assays have been used in medicine for over 50 years as a screening test for monoamine-secreting tumors, such as pheochromocytoma and carcinoid syndrome. In these disease states, when the result of a spot baseline monoamine assay is above the specific value set by the laboratory, it is an indication to obtain a 24-hour urine sample to make a definitive diagnosis. There are no defined applications where spot baseline urinary monoamine assays can be used to diagnose disease or other states directly. No peer-reviewed published original research exists which demonstrates that these assays are valid in the treatment of individual patients in the clinical setting. Since 2001, urinary monoamine assay sales have been promoted for numerous applications under the “spot baseline urinary neurotransmitter testing marketing model”. There is no published peer-reviewed original research that defines the scientific foundation upon which the claims for these assays are made. On the contrary, several articles have been published that discredit various aspects of the model. To fill the void, this manuscript is a comprehensive review of the scientific foundation and claims put forth by laboratories selling urinary monoamine assays under the spot baseline urinary neurotransmitter testing marketing model. |
|
Microperforation Prolotherapy™: a novel method for successful
nonsurgical treatment of atraumatic spontaneous anterior
sternoclavicular subluxation with an illustrative case Abstract: Surgical repair of an atraumatic spontaneous anterior subluxation of the sternoclavicular joint (herein referred to as the “SCJ”) is often associated with poor outcome expectations. With traditional treatment, successful conservative therapy usually incorporates major lifestyle alterations. This manuscript discusses a novel approach known as "microperforation prolotherapy."™ To illustrate the technique, the care of a patient who benefitted from this treatment is reviewed. |
|
The
dual-gate lumen model of renal monoamine transport Abstract: The three-phase response of urinary serotonin and dopamine in subjects simultaneously taking amino acid precursors of serotonin and dopamine has been defined. No model exists regarding the renal etiology of the three-phase response. This writing outlines a model explaining the origin of the three-phase response of urinary serotonin and dopamine. A “dual-gate lumen transporter model” for the basolateral monoamine transporters of the kidneys is proposed as being the etiology of the three-phase urinary serotonin and dopamine responses. |
|
Abstract: This writing discusses a case study of a 37-year-old white male with a 22 year history of progressive and severe Crohn’s disease, with no previous remissions, that showed dramatic and relatively abrupt remission of symptoms when a novel treatment approach was prescribed. This treatment protocol involved the balancing of serotonin and dopamine through the organic cation transporters (OCT) with the guidance of OCT analysis interpretation. |
|
Neurotransmitter
testing of the urine: a comprehensive analysis Abstract: This paper analyzes the statistical correlation of urinary serotonin and dopamine data in subjects not suffering from monoamine-secreting tumors such as pheochromocytoma or carcinoid syndrome. Peer-reviewed literature and statistical analyses were searched and monoamine (serotonin and dopamine) assays defined in order to facilitate their proper interpretation. Many research findings in the literature are novel. Baseline assays completed with no monoamine precursors differ from baseline assays performed on a different day in the same subject. There is currently no scientific basis, value, or predictability in obtaining baseline monoamine assays. Urinary assays performed while taking precursors can demonstrate a lack of correlation or unexpected correlations such as inverse relationships. The only valid model for interpretation of urinary monoamine assays is the “three-phase model” which leads to predictability between monoamine assays and precursor administration in varied amounts. |
|
ADHD
Study: Treatment with Amino Acids 85 children with ADHD treated with amino
amino acids and OCT assay interpretation with results that
appear superior to prescription ADHD drugs.
|
|
Treatment
of Parkinson's Disease L-dopa holds the highest potential in the treatment of Parkinson disease. Its potential is limited by mis-management of amino acids and use of carbidopa. This paper outlines proper management of L-dopa in the treatment of Parkinson disease. |
|
Differentiating
Garden Variety Depression from Bipolar Depression with Amino
Acids Differentiating depressive dominant bipolar disorder from garden variety depression with amino acids guided by OCT assay interpretation. |
|
The
Urinary Neurotransmitter Testing Model Discredited - Part
One The peer-reviewed scientific paper that exposed
and discredited |
|
The
Urinary Neurotransmitter Testing Model Discredited - Part
Two A second paper discrediting the "urinary neurotransmitter testing model." |
